ENDOTHELIAL CELL PROLIFERATION ACTIVITY IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER: AN IN VITRO MODEL FOR ASSESSMENT
- 1 February 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 159 (2) , 465-470
- https://doi.org/10.1016/s0022-5347(01)63949-1
Abstract
Purpose: Urinary excretion of several pro-angiogenic and antiangiogenic substances has been correlated with malignant tumor growth. The aim of this study was to assay angiogenic activity in urine from patients with cancer of the prostate and benign prostatic hyperplasia (BPH). Materials and Methods: Urine specimens from 22 healthy male volunteers (control), 33 patients with BPH and 29 with organ confined prostate cancer were analyzed for angiogenic activity in a bovine capillary endothelial cell proliferation assay. In parallel the concentration of basic fibroblast growth factor and vascular endothelial growth factor was determined by enzyme immunoassay in the corresponding urine specimens. Results: Urine samples from patients with BPH and prostate cancer increased bovine capillary endothelial cell proliferation by 13.1% and 15.1%, respectively, whereas urine from the control group showed a significantly lower angiogenic activity, increasing endothelial cell proliferation by only 0.7% (p = 0.001). Urinary basic fibroblast growth factor and vascular endothelial growth factor were highest in patients with BPH and lowest in the group with prostate cancer (p = 0.0001). Conclusions: Urine from patients with BPH and prostate cancer stimulates endothelial cell proliferation activity. The degree of endothelial cell stimulation does not correlate with the concentration of basic fibroblast growth factor or vascular endothelial growth factor. Whether the observed pro-angiogenic activity is due to an increased production or release of (an) other angiogenic factor(s) and/or loss of (an) angiogenesis inhibitor(s), deserves further investigation.Keywords
This publication has 26 references indexed in Scilit:
- Editorial: Prostate Cancer–Many Treatments But Not Enough AnswersJournal of Urology, 1995
- Urinary excretion of growth factors in patients with ovarian cancerEuropean Journal Of Cancer, 1994
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994
- Predictors of pathologic stage in prostatic carcinoma. The role of neovascularityCancer, 1994
- Increased Immunodetection of Acidic Fibroblast Growth Factor in Bladder Cancer, Detectable in UrineJournal of Urology, 1993
- Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer PatientsJNCI Journal of the National Cancer Institute, 1993
- Comparison of microscopic vascularity in benign and malignant prostate tissueHuman Pathology, 1993
- Epidermal Growth Factor in Urine from the Patients with Urothelial TumorsUrologia Internationalis, 1992
- Urinary epidermal growth factor concentrations in various human malignanciesBritish Journal of Cancer, 1988
- Epidermal Growth Factor in Urine from Patients with Urinary Bladder TumorsEuropean Urology, 1988